Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., and Ube Corp. have received FDA approval for their Omlonti 0.002 percent eye drops, which are designed to reduce elevated intraocular pressure in glaucoma patients.
FDA approves eye drops for the reduction of intraocular pressure
